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Sebastian Kelle, MD,* Amedeo Chiribiri, MD,† Juliane Vierecke, MD,*
Christina Egnell, MD,* Ashraf Hamdan, MD,‡ Cosima Jahnke, MD,* Ingo Paetsch, MD,*
Ernst Wellnhofer, MD,* Eckart Fleck, MD,* Christoph Klein, MD,* Rolf Gebker, MD*
Berlin, Germany; London, United Kingdom; and Tel Aviv, Israel
O B J E C T I V E S The aim of this study was to assess the long-term value of high-dose dobutamine
cardiac magnetic resonance (DCMR) for the prediction of cardiac events in a large cohort of patients with
known or suspected coronary artery disease.
B A C KG ROUND High-dose DCMR has been shown to be a useful technique for diagnosis and
intermediate-term prognostic stratiﬁcation.
METHOD S Clinical data and DCMR results were analyzed in 1,463 consecutive patients undergoing
DCMR between 2000 and 2004. Ninety-four patients were lost to follow-up. The remaining 1,369 patients
were followed up for a mean of 44  24 months. Cardiac events, deﬁned as cardiac death and nonfatal
myocardial infarction, were related to clinical and DCMR results.
R E S U L T S Three-hundred ﬁfty-two patients underwent early revascularization (3 months of DCMR)
and were excluded from analysis. Of the remaining 1,017 patients, 301 patients (29.6%) experienced
inducible wall motion abnormalities (WMA). Forty-six cardiac events were reported. In those with and
without inducible WMA, the proportion of patients with cardiac events was 8.0% versus 3.1%,
respectively, p 0.001 (hazard ratio: 3.3; 95% conﬁdence interval: 1.8 to 5.9 for the presence of inducible
WMA; p  0.001). A DCMR without inducible WMA carried an excellent prognosis, with a 6-year cardiac
event-free survival of 96.8%. In all 1,369 patients in the patient group with stress-inducible WMA, those
patients with medical therapy demonstrated a trend to a higher cardiac event rate (8.0%) than those
with early revascularization (5.4%) (p  0.234). Patients with normal DCMR and medical therapy or early
revascularization demonstrated similar cumulative cardiac event rates (3.1% vs. 3.2%, p  0.964).
CONC L U S I O N S In a large cohort of patients, DCMR has an added value for predicting cardiac
events during long-term follow-up, improving the differentiation between high-risk and low-risk
patients. Patients with inducible WMA and following early revascularization, demonstrate lower cardiac
event rates than patients with medical therapy alone. (J Am Coll Cardiol Img 2011;4:161–72) © 2011
by the American College of Cardiology Foundation
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162igh-dose dobutamine cardiac magnetic res-
onance (DCMR) is a useful technique for
diagnosis (1–3) and prognostic stratification
of patients with known or suspected coro-
ary artery disease (CAD) (4–8). Patients without
tress-induced wall motion abnormalities (WMAs)
n DCMR have been reported to have a low event
ate at short- and intermediate-term follow-up
mean follow-up: 40  24 months; median follow-
p: 27 months) (4–8).
See page 173
However, it is not known whether the
low-risk guarantee of a DCMR without
inducible WMA can be maintained for
longer-term follow-up and whether pa-
tients with a normal study might require
repeat testing. Assessment of the long-
term prognosis of DCMR is important,
because the test might not only identify
high-risk patients in whom further inter-
ventions are necessary but also distinguish
low-risk patients in whom additional pro-
cedures and intensive medical follow-up
are not required.
In addition, current available reports
about the prognostic value of DCMR are
limited by the small numbers of patients
and cardiac events (4–8).
Accordingly, we performed this study
to determine the long-term prognostic
utility of DCMR results for forecasting
future cardiac events in a large cohort of
patients with known or suspected CAD.
M E T H O D S
Study population and design. Consecutive
patients (n  1,463) with known or sus-
pected CAD, who were clinically referred for mag-
netic resonance imaging (MRI) to assess cardiac
function and to test for ischemia with high-dose
dobutamine were enrolled between 2000 and 2004.
A few of the patients in the current study were also
included in previous studies evaluating the prognos-
tic value of a combined protocol for ischemia testing
(with high-dose dobutamine and adenosine) (n 
123 patients [8.4% of the whole study population])
(5), comparing infarct size relative to left ventricular
(LV) function/volumes (9) and infarct size relative
to contractile reserve with low-dose dobutamine (n
ass
se
c
ar
ion
y
n
ality
dex 111 patients [7.6% of the whole study popula- ition]) (10). The current study evaluates the relative
merits of high-dose DCMR for the prediction of
long-term prognosis in a large cohort of patients.
Patients with contraindications for MRI (non-
compatible biometallic implants or claustrophobia)
or contraindications for administration of dobut-
amine (severe arterial hypertension [220/120 mm
Hg], unstable angina pectoris, significant aortic
stenosis [aortic valve mean gradient50 mm Hg or
ortic valve area 1 cm2], complex cardiac arrhyth-
ias, significant hypertrophic obstructive cardio-
yopathy, myocarditis, endocarditis, and pericardi-
is) were excluded from enrollment (11). Informed
onsent was obtained from all patients. The study
as conducted in accordance with the standards of
he Charité institutional ethics committee.
MRI. As previously described, DCMR stress images
ere collected on a 1.5-T Gyroscan ACS-NT/Intera
RI scanner (Philips Healthcare, Best, the Nether-
ands) equipped with Powertrack 6000 gradients and a
-element cardiac synergy coil (5). Patients were posi-
ioned in the supine position. Three short-axis views
apical, mid-ventricular, basal) and 3 long-axis views (4-,
-, and 3-chamber) were acquired during breath-holds of
pproximately 8 s with vectorcardiographic gating.
The heart was imaged according to the recommen-
ations of the Society for Cardiovascular Magnetic
esonance (12) with a balanced, fast-field echo se-
uence with parallel imaging (SENSE, acceleration
actor 2). Typical parameters were a field of view of
00  400 mm2, matrix of 256  256 pixels, slice
thickness of 10.00 or 8.00 mm, flip angle of 50°, time
to echo of 1.82 ms, and time to repeat of 3.65 ms.
Temporal resolution was 25 to 50 ms.
DCMR. Patients were generally instructed to discon-
inue beta-blockers 24 h before DCMR, unless the
eferring physician did not approve this. The im-
ging methodology of high-dose DCMR has been
escribed in detail previously (2). Briefly, high-dose
CMR was performed with the standard high-
ose regimen (dobutamine up to 40 g/kg1/
min1) plus atropine (up to 2 mg) if needed to
each the target heart rate, defined as 85% maxi-
um exercise, adjusted for age. Magnetic resonance
arameters were identical at rest and during high-
ose DCMR. Termination criteria were as previ-
usly published (11). Myocardial ischemia (positive
CMR) was defined as a new (induced) or wors-
ning WMA or a biphasic response in 1 segment
f the LV during infusion of dobutamine. As a
afety precaution, dobutamine infusion and imaging
ere terminated at the earliest detection of WMAsA B B R E V I A T I O N S
A N D A C R O N YM S
CABG coronary artery byp
grafting
CAD coronary artery disea
CI confidence interval
DCMR dobutamine cardia
magnetic resonance
DSE dobutamine stress
chocardiography
R hazard ratio
GE late-gadolinium
nhancement
V left ventricle/ventricul
LVEF left ventricular eject
fraction
MImyocardial infarction
MRImagnetic resonance
imaging
PCI percutaneous coronar
intervention
RWMA resting wall motio
abnormality
WMAwall motion abnormn 2 adjacent segments. Images were analyzed
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163during and immediately after the examination by 2
experienced investigators with a quad screen for-
mat. Differences in classification were decided in a
consensus review. Cine images were analyzed with-
out post-processing. Determination of interob-
server variability was already reported in a previous
study (5).
MRI analysis. To determine global function, endo-
ardial borders were outlined manually on long-axis
ine images with previously validated software
ViewForum, Philips). Papillary muscles were re-
arded as part of the ventricular cavity. Left ven-
ricular end-systolic volume, LV end-diastolic vol-
me, and left ventricular ejection fraction (LVEF)
ere calculated. End-diastolic basal septal wall
hickness was measured quantitatively.
For segmental analysis of LV function, the standard
7-segment model was used (13). LV wall motion was
ssessed with a visual scoring system in which 0 
ormal wall motion, 1mild hypokinesia, 2 severe
ypokinesia, 3  akinesia, and 4  dyskinesia. Wall
otion score index (WMSI), assessed at rest and
uring maximum stress, was defined as the cumulative
um of individual segment scores divided by the
umber of interpreted segments. The change (delta)
n WMSI and LV function from rest to high-dose
CMR was recorded.
Follow-up. The long-term follow-up was performed
by hospital chart review and telephone contact.
Cardiac events were assessed by physicians who
were unaware of the former stress test results of
Figure 1. Composition of the Study Population
Early revascularization was deﬁned as percutaneous coronary interv
dobutamine cardiac magnetic resonance (DCMR). WMA  wall motionpatients. The date of the last interview or review
was used to calculate follow-up time. Follow-up
was completed in 2009 and was successful in 1,369
of 1,463 (94%) patients (Fig. 1). The patient
population with complete follow-up was split ini-
tially, depending on DCMR results. This resulted
in a study population of 811 of 1,369 (59.2%)
patients with DCMR without inducible WMA and
558 of 1,369 (40.8%) patients with inducible
WMA. Cardiac risk factors for the whole study
population and a comparison of risk factors between
patients with positive and negative DCMR are
demonstrated in Table 1.
To avoid the possibility of a cardiac event result-
ing from early revascularization procedure (within 3
months after DCMR), 352 of 1,369 (25.7%) pa-
tients with percutaneous coronary intervention
(PCI) and coronary artery bypass grafting (CABG)
within the first 3 months after DCMR were ex-
cluded (Fig. 1). This resulted in 1,017 patients for
general analysis.
In a subgroup analysis, cumulative cardiac event
rates were compared between patients with early
revascularization (352 patients) and the remaining
1,017 patients with regard to DCMR result and
after therapy (3 months of DCMR).
The primary end point was the occurrence of
cardiac events defined as cardiac death (caused by
end-stage heart failure, acute myocardial infarction
(MI), or sudden cardiac death) and nonfatal MI (9).
Nonfatal MI was defined by clinical presentation,
on (PCI) or coronary artery bypass grafting (CABG) 3 months ofenti
abnormality.
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164elevated cardiac enzyme levels, and/or typical
changes in the electrocardiogram. Patients were
censored at the time of the cardiac event.
Other events (termed any events) included car-
diac events, noncardiac death, revascularization by
PCI or CABG, and hospital stay due to ventricular
arrhythmia, unstable angina, or congestive heart
failure. In the case of 2 simultaneous cardiac events,
the worst event was selected for use in follow-up
(cardiac death  nonfatal MI  revascularization 
ospital admission).
In accordance with dobutamine stress echocardi-
graphy (DSE) studies, in patients with DCMR
ithout inducible WMA who were treated medically
716 of 1,017 patients), the annual cardiac event rate
as reported (14). In addition, the cardiac event rate
n the first 3 years and from the fourth to the sixth year
f follow-up was recorded (15).
Statistical analysis. Statistical analysis was per-
ormed with SPSS for Windows (release 18.0;
PSS, Chicago, Illinois). All continuous parameters
re given as mean  1 SD. Categorical data are
ummarized as frequencies and percentages. Differ-
nces in baseline characteristics between patients
ho reached the primary end point and those who
id not were analyzed with the Wilcoxon Mann-
hitney U test for continuous variables and the
hi-square test for dichotomous variables.
We aimed to study to what extent MRI results
ere associated with cardiac events. For this pur-
ose, all clinical and MRI data with a p value 0.1
in a comparison between patients with and without
he occurrence of cardiac events) were eligible. Cox
Table 1. Composition of the Study Population
Variable
Total Population
(n  1,369)
With
Age (yrs) 61.6 10.1
Sex (men) 961 (70.2)
BMI (kg/m2) 27.4 3.9
Diabetes mellitus 249 (18.2)
Hypertension 1,047 (76.6)
HLP 1,024 (74.9)
Smoker 627 (45.9)
Family history CAD 488 (35.7)
Previous CAD 800 (58.5)
Previous PCI/CABG 654 (47.8)
No. of risk factors 3.1 1.3
RWMA 594 (43.4)
BMI  body mass index; CABG  coronary artery bypass grafting; CAD 
HLP  hyperlipoproteinemia; MI  myocardial infarction; PCI  percutaneoroportional hazard regression models were con- structed for clinical and MRI variables. The vari-
bles seemed to be associated with cardiac events at
he p 0.1 level in univariable analysis. Unadjusted
nd adjusted hazard ratios (HRs) with their corre-
ponding 95% confidence intervals (CIs) are re-
orted. We selected a multivariable Cox propor-
ional hazards regression model by a forward/
ackward inclusion strategy of potential cardiac risk
actors and MRI data in a model limited to 4
arameters. Selection and deselection were based on
ald statistics. Potential parameters tested were all
arameters with p  0.1 in univariate analysis.
The C-statistic in binary outcome is equivalent
o the area under the curve (16). We evaluated
he Cox regression predictor for all 4 models over
years and constructed area under the curve
tatistics. Significance was evaluated by the De-
ong test (17).
After adjustment for multiple confounders,
tress-induced WMA as determined by MRI
eemed significantly related with cardiac events.
herefore, in a Kaplan-Meier analysis, the medi-
ally treated study population was divided into 2
roups, on the basis of DCMR result. Difference in
urvival over time was evaluated by a log-rank test.
We tested early revascularization as a time-
ependent covariate in a Cox regression model and
id not find any significant impact of time regarding
CMR results and outcome. Early revascularization
as a significant independent risk, however (p 
.001).
For all tests, p  0.05 was considered statistically
WMA on DCMR
 811)
Inducible WMA
(n  558) p Value
.1 10.5 61.9 9.4 0.135
42 (66.9) 419 (75.2) 0.001
.3 4.0 27.6 3.9 0.109
23 (15.2) 126 (22.6) 0.001
89 (72.7) 458 (82.2) 0.001
72 (70.6) 452 (81.1) 0.001
57 (44.1) 270 (48.5) 0.086
84 (35.0) 204 (36.6) 0.695
29 (52.9) 371 (66.6) 0.001
47 (42.8) 307 (55.1) 0.001
.9 1.3 3.3 1.3 0.001
90 (35.8) 304 (54.6) 0.001
ronary artery disease; DCMR  dobutamine cardiac magnetic resonance;
oronary intervention; RWMA  resting wall motion abnormality.out
(n
61
5
27
1
5
5
3
2
4
3
2
2
co
us cignificant. All tests were 2-sided.
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165R E S U L T S
Study population. Of all patients included, 94 of
1,463 (6.5%) experienced arrhythmias at the time of
DCMR. There was no hard event during DCMR
testing. Patients with arrhythmias during testing did
not differ significantly with regard to the number of
cardiac events at long-term follow-up from patients
without arrhythmias during DCMR, p  0.126.
The study population consisted of 301 of 1,017
(29.6%) patients with inducible WMA and 716 of
1,017 (70.4%) patients with DCMR without induc-
Table 2. Clinical Data
Variable
Total Population
(n  1,017)
Age (yrs) 61.2 10.5
Sex (men) 689 (67.7)
BMI (kg/m2) 27.4 4.0
Diabetes mellitus 171 (16.8)
Hypertension 743 (73.1)
HLP 715 (70.4)
Smoker 443 (43.6)
Family history CAD 357 (35.1)
Previous CAD 529 (52)
Previous Q-wave MI 251 (24.7)
Previous PCI/CABG 435 (42.8)
No. of risk factors 3.0 1.3
-blocker 566 (55.7)
Calcium channel blocker 194 (19.1)
ACE inhibitor 621 (61.1)
Warfarin/aspirin 722 (71)
Statin 548 (53.9)
Nitrate 198 (19.5)
Diuretic 285 (28.0)
Continuous data are expressed as mean  1 SD; categorical data are summari
ACE  angiotensin-converting enzyme; other abbreviations as in Table 1.
Table 3. Hemodynamic Data
Variable
Total Population
(n  1,017)
Resting HR (beats/min) 71 13
Peak HR (beats/min) 136 18
MPHR reached 785 (77.2)
Resting SBP (mm Hg) 134 48
Peak SBP (mm Hg) 151 79
Resting DBP (mm Hg) 72 11
Peak DBP (mm Hg) 72 29
Rest rate/pressure product 9,530 3,524
Peak rate/pressure product 20,598 11,362
Hemodynamic data from the participants are demonstrated. Continuous data a
percentages.
DBP  diastolic blood pressure; HR  heart rate; MPHR  maximum age-relatedible WMA. Clinical data are presented in Table 2,
and hemodynamic data from the participants are
shown in Table 3. As demonstrated in Table 2, age,
diabetes mellitus, hypercholesterolemia, previous
CAD or revascularization, and absolute number of
risk factors were significantly lower in patients
without than in patients with cardiac events.
Of those patients with early revascularization,
257 of 352 (73.0%) had inducible WMA; 95 of 352
(27.0%) had a negative DCMR. Patients who
received early revascularization demonstrated a
greater extent of ischemia (number of segments
Events: No
(n  971)
Events: Yes
(n  46) p Value
61.0 10.5 64.6 8.9 0.024
652 (67.3) 38 (82.6) 0.032
27.4 4.0 27.6 3.9 0.714
154 (15.9) 17 (37.0) 0.001
708 (73.0) 35 (76.1) 0.670
676 (69.7) 39 (84.8) 0.029
419 (43.2) 24 (52.2) 0.079
340 (35.0) 17 (37.0) 0.843
489 (50.4) 40 (87.0) 0.001
230 (23.7) 21 (45.7) 0.001
401 (41.3) 34 (73.9) 0.001
2.9 1.3 3.4 1.5 0.014
530 (54.6) 36 (78.3) 0.002
178 (18.3) 16 (34.8) 0.005
588 (60.5) 33 (71.7) 0.249
677 (69.7) 45 (97.8) 0.001
509 (52.4) 39 (84.8) 0.001
177 (18.2) 21 (45.7) 0.001
262 (27.0) 23 (50) 0.001
s frequencies and percentages.
Events: No
(n  971)
Events: Yes
(n  46) p Value
71 13 70 12 0.496
136 18 131 20 0.057
754 (77.7) 31 (67.4) 0.100
134 49 131 26 0.674
152 80 142 34 0.417
72 11 70 12 0.193
72 30 70 14 0.564
9,552 3,575 9,090 2,165 0.385
20,694 11,567 18,582 5,184 0.218
pressed as mean  1 SD; categorical data are summarized as frequencies andzed are expredicted heart rate; SBP  systolic blood pressure.
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166with new WMA at DCMR 3.3  2.7 vs. 1.8  2.6
in medically treated patients, p  0.001). Patients
ho received early revascularization included a sig-
ificantly higher proportion of subjects with diabe-
es (22% vs. 17%, p 0.024), hypertension (87% vs.
3%, p  0.001), hyperlipoproteinemia (88% vs.
70%, p 0.001), previous CAD (77% vs. 52%, p
0.001), previous revascularization (62% vs. 43%,
p  0.001), a higher number of cardiovascular risk
factors (3.4  1.1 vs. 3.0  1.3, p  0.001), and
resting wall motion abnormality (RWMA) (58% vs.
39%, p  0.001) compared with patients with
medical therapy.
In patients with DCMR without inducible
WMA, 95 of 811 patients (11.7%) underwent early
revascularization. In comparison with patients with
DCMR without inducible WMA and medical
therapy (716 of 811 patients), those with DCMR
without inducible WMA and early revasculariza-
tion demonstrated significantly more previous
CAD (86% vs. 49%, p  0.001), previous revascu-
larization (72% vs. 39%, p  0.001), a higher
number of cardiovascular risk factors (3.4  1.1 vs.
2.9  1.3, p  0.001), and RWMA (57% vs. 33%,
p  0.001).
In a comparison of the risk profile in patients with
inducible WMA, patients with early revascularization
demonstrated significantly more hypertension (88%
vs. 78%; p  0.003), hyperlipoproteinemia (86% vs.
77%; p  0.008), previous CAD (74% vs. 61%; p 
0.001), and an increased number of cardiovascular risk
factors (3.4 1.1 vs. 3.2 1.3, p 0.013) compared
with patients treated medically.
In the 94 patients lost to follow-up, the overall
study composition was not significantly different
from that of the remaining study population with
complete follow-up. In addition, in comparing the
risk profile, there was a significantly lower age
(57  12 years vs. 61  10 years, p  0.001) and a
lower number of patients with previous CAD (39%
vs. 59%, p  0.001). Patients lost to follow-up also
demonstrated a significantly lower rate of inducible
WMA (40.7% vs. 17%; p  0.001).
Clinical outcome of patients during follow-up. The
average duration of follow-up was 44 24 months,
with a median of 38 months (24; 59); 46 patients
(4.5%) suffered from a cardiac event during follow-
up. Mean time between DCMR and cardiac event
was 36  18 months. Thirty-three patients (3.2%)
had cardiac death, and 13 patients (1.3%) developed
nonfatal MI during follow-up. Noncardiac death
was reported in 23 patients (2.3%). Furthermore,
109 patients (10.7%) were hospitalized during hfollow-up, because of ventricular arrhythmias (5
patients, 0.5%) or unstable angina (104 patients,
10.2%). One hundred and fifteen patients (11.3%)
underwent PCI, and 33 patients (3.2%) underwent
CABG 3 months after MRI.
In those patients who underwent revascularization
3 months after DCMR due to inducible WMA, 14
(5.4%) cardiac events were reported. Seven of 257
patients (2.7%) had cardiac death and 7 of 257 (2.7%)
developed nonfatal MI during follow-up. In the re-
maining 95 patients with DCMR without inducible
WMA who underwent early revascularization, 3
(3.2%) cardiac events were reported. Two patients
(2.1%) had cardiac death, and 1 patient (1.1%) devel-
oped nonfatal MI during follow-up.
The outcome of all patients with complete
follow-up dependent on DCMR result and the
following therapy (medical treatment or early revas-
cularization) is shown in Figure 3.
MRI variables. The MRI findings are listed in Table 4.
VEF was significantly higher in patients without
han in patients with cardiac events. As demon-
trated, left ventricular end-systolic volume, left
entricular end-diastolic volume, the number of
ysfunctional segments at rest and stress, WMSI at
est and stress, and inducible WMA were signifi-
antly associated with cardiac events. Approxi-
ately 30% of the patients experienced an inducible
MA during testing.
Predictive value of clinical data and DCMR results. A
nivariable Cox model was used to identify the
redictive value for cardiac events for all clinical
ata and MRI data (Table 5). Inducible WMA was
n independent predictor of cardiac events in this
atient population (HR: 3.3, CI: 1.8 to 5.9, p 
.001).
Multivariate predictors of cardiac events are pre-
ented in Table 6. Inducible WMA during testing
emained an adverse predictor of cardiac events
HR: 3.0, 95% CI: 1.6 to 5.4, p  0.001).
The chi-square value was different between pa-
ients with previous CAD alone (chi-square: 23.0)
nd those with additional diabetes mellitus (chi-
quare: 34.5). The overall chi-square value was
ncreased further by adding WMSI at rest (chi-
quare: 73.9) and inducible WMA (chi-square: 86.5).
The receiver-operator characteristic curve (Fig. 2)
emonstrates that there was a significant difference
etween the models including WMSI at rest and
hose based on clinical parameters only (p 0.003).
dding a positive DCMR shows no significant
ifference in the other parameters (p  0.693);
owever, it showed a trend for higher sensitivity
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167and specificity, demonstrated by a higher cutoff
value (red colored ring in Figure 2).
In medically treated patients with and without
nducible WMA, the proportion of patients with
ardiac events was 8.0% versus 3.1%, respectively,
p  0.001). In the patient group with inducible
MA those patients with medical therapy demon-
trated a trend to a higher cardiac event rate (8.0%)
han those with early revascularization (5.4%) (p 
.234). Patients with DCMR without inducible
MA and medical therapy or early revasculariza-
ion demonstrated similar cumulative cardiac event
ates (3.1% vs. 3.2%, p  0.964) (Fig. 3).
Patients were separated according to DCMR
esult (patients with inducible WMA  patients at
high risk; n  301 [29.6%]) and were compared
with patients without inducible WMA  patients
at low-risk (n  716 [70.4%]) for cardiac events. A
Kaplan-Meier analysis of the cardiac event rate and
rate of any events, in those with and without
inducible WMA, is shown in Figure 4. A DCMR
without inducible WMA carried an excellent prog-
nosis, with an annual cardiac event rate of 1.1% over
6 years (0.8% in the first 3 years, and 1.4% between
the fourth and sixth year).
Of 1,017 patients, 392 demonstrated RWMA; in
156 (39.8%) a positive DCMR was reported, and in
625 patients without RWMA, 145 (23.2%) showed
a positive DCMR. In patients without RWMA, we
found only a difference within the first 3 years; after
that there is no significant difference in outcome
regarding a DCMR without inducible WMA. In
patients with RWMA, a positive DCMR adds a
significant value for the prediction of outcome (p 
Table 4. Magnetic Resonance Imaging Data
Variable
Total Populat
(n  1,017
LVEF (%) 57.2 10.3
LVEF (%) 40% 64 (6.3)
LVESV (ml) 65.8 37.3
LVEDV (ml) 149.0 59.6
End-diastolic wall thickness (mm) septum 10.4 2.6
RWMA 392 (38.5)
No. of dysfunctional segments at rest 1.6 2.8
No. of dysfunctional segments at stress 1.8 2.6
WMSI at rest 0.1 0.2
WMSI at maximum stress 0.2 0.3
∆ WMSI 0.0 0.1
Inducible WMA on DCMR 301 (29.6)
Continuous data are expressed as mean  1 SD; categorical data are summari
LVEF  left ventricular ejection fraction; LVEDV  left ventricular end-diastolic
abnormality; WMSI  wall motion score index.0.001).D I S C U S S I O N
The main finding of this study is that in a large
cohort of patients DCMR provides additional in-
dependent information on risk stratification during
Events: No
(n  971)
Events: Yes
(n  46) p Value
57.4 9.8 52.3 18.0 0.001
55 (5.7) 9 (20.5) 0.001
64.4 34.0 95.4 75.9 0.001
148.0 58.2 176.0 80.4 0.002
10.4 2.6 11.1 2.4 0.049
360 (37.1) 32 (69.6) 0.001
1.5 2.6 4.4 4.3 0.001
1.7 2.5 4.0 3.5 0.001
0.1 0.2 0.4 0.4 0.001
0.2 0.2 0.4 0.4 0.001
0.0 0.1 0.0 0.2 0.333
277 (28.5) 24 (52.2) 0.001
s frequencies and percentages.
me; LVESV  left ventricular end-systolic volume; RWMA  resting wall motion
Table 5. Univariate Analysis for Prediction of Cardiac Events
Hazard
Ratio
95% Conﬁ
Interv
Age 1.036 1.006–1.
Sex (male) 0.466 0.229–0.
Previous CAD 6.245 2.648–14
Previous MI 2.513 1.433–4.
Previous revascularization 3.972 2.056–7.
Aspirin/warfarin 19.158 2.641–13
Statins 5.352 2.393–11
Ca-channel blocker 2.270 1.237–4.
-blocker 3.110 1.543–6.
Diuretics 2.693 1.508–4.
Nitrates 3.560 1.992–6.
Hyperlipoproteinemia 2.472 1.106–5.
Diabetes 3.175 1.742–5.
No. of risk factors 1.310 1.046–1.
LVEF (rest) 0.958 0.935–0.
LVEF (rest) 40% 4.012 1.928–8.
LVEDV 1.004 1.002–1.
LVESV 1.013 1.009–1.
WMSI (rest) 10.730 5.482–21
No. of dysfunctional segments at rest 1.230 1.160–1.
RWMA 3.732 1.991–6.
WMSI (stress) 9.834 4.902–19
No. of dysfunctional segm. at stress 1.244 1.163–1.
Inducible WMA on DCMR 3.278 1.832–5.
Only clinical or magnetic resonance imaging data with signiﬁcant p values in
presented.ion
)
zed a
voludence
al p Value
067 0.019
949 0.035
.731 0.001
408 0.001
671 0.001
8.990 0.003
.974 0.001
167 0.008
267 0.002
810 0.001
362 0.001
528 0.027
785 0.001
641 0.018
981 0.001
347 0.001
006 0.001
017 0.001
.001 0.001
304 0.001
994 0.001
.728 0.001
331 0.001
866 0.001
univariable analysis areAbbreviations as in Table 4.
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168long-term follow-up. A positive result forecasts a
higher rate of cardiac events. We found a high
negative predictive value of DCMR: it improves the
differentiation between high- and low-risk patients
after accounting for known clinical predictors of car-
diac events. Patients with inducible WMA and after
early revascularization demonstrate lower cardiac
event rates than patients with medical therapy alone.
Several studies have demonstrated a high sensi-
tivity and specificity of DCMR in the detection of
WMA (3). It has been reported to be a safe method
for the diagnosis of CAD (18). Previous studies
have highlighted the utility of DCMR stress to
forecast cardiac prognosis and reported a low car-
diac event rate at short- and intermediate-term
Figure 2. ROC Curve Illustrating Prognostic Value of DCMR
Receiver-operator characteristic (ROC) curve illustrating prognostic v
The addition of DCMR provides incremental prognostic information
and diabetes mellitus). Furthermore, the addition of wall motion sc
prognostic information over baseline clinical variables and showed
higher cutoff value (red colored ring). AUC  area under the recei
Table 6. Multivariable Cox Proportional Hazard Model for
Prediction of Cardiac Events
Hazard Ratio
95% Conﬁdence
Interval p Value
Diabetes mellitus 2.244 1.225–4.111 0.009
Previous CAD 3.234 1.311–7.975 0.011
WMSI (rest) 7.203 3.301–15.717 0.001
Inducible WMA
on DCMR
2.992 1.639–5.396 0.001
WMSI  wall motion score index; other abbreviations as in Table 1.wall motion abnormality.follow-up after a DCMR without inducible WMA
(4–8). In this study, we reported on a relatively
large number of patients with a longer mean
follow-up duration after DCMR (44  24
months). However, currently available reports about
the prognostic value of DCMR are also limited by
the small number of patients and cardiac events.
Well-established existing risk factors for cardiac
events, such as previous MI, diabetes mellitus, and
WMA at rest (represented by WMSI at rest) were
prevalent in the patients participating in this study
and were notably disproportionally distributed be-
tween patients with and without cardiac events. To
address whether the presence of risk factors in the 2
study groups influenced our results, we performed
multivariable regression analysis to determine the
prognostic utility of DCMR stress results after
accounting for the presence of these risk factors.
We demonstrated that inducible WMA (Table 6)
identified during DCMR independently predicted
future cardiac events (HR: 3.0, 95% CI: 1.6 to 5.4,
p  0.001). The receiver-operator characteristic
curve demonstrates that the addition of DCMR to
known clinical risk factors showed a trend for
higher sensitivity and specificity, demonstrated by a
higher cutoff value (Fig. 2). This demonstrates the
e of dobutamine cardiac magnetic resonance (DCMR) in patients.
baseline clinical variable (previous coronary artery disease [CAD]
index (WMSI) at rest to DCMR results adds further incremental
nd for higher sensitivity and speciﬁcity, demonstrated by a
perator characteristic curve; CI  conﬁdence interval; WMA alu
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169incremental value of DCMR over clinical predic-
tors.
In patients with DCMR without inducible
WMA, the annual cardiac event rate was 1.1%
(0.8% in the first 3 years, and 1.4% from the fourth
to the sixth year). Our results demonstrated that the
low-risk warranty of a DCMR without inducible
WMA was sustained during 3 years after DCMR.
However, similar to DSE, the cardiac event rate was
still relatively low after 3 years, and a follow-up study
at that interval was recommended because the cardiac
event rate almost doubled at later follow-up (15).
Furthermore, the addition of WMSI at rest to
DCMR results adds further incremental prognostic
information over baseline clinical variables. As
shown in previous studies, parameters representing
impaired LV function and parameters representing
the presence or extent of CAD (known CAD;
inducible WMA) or a high likelihood of CAD
(diabetes mellitus) were related to the occurrence of
cardiac events at long-term follow-up (14). This is
to our knowledge the first study using DCMR to
confirm these results in a large study population. In
patients with inducible WMA treated medically the
rate of cardiac death or nonfatal MI was increased
2.6-fold. In medically treated patients with and
without inducible WMA, the proportion of pa-
tients with cardiac events was 8.0% versus 3.1%,
respectively, (p  0.001). In the patient group with
nducible WMA, those patients with medical ther-
py only demonstrated a trend to a higher cardiac
vent-rate (8.0%) than those with early revascular-
zation (5.4%) (p  0.234). This analysis demon-
trates a possible association between early revascu-
arization and improved survival among patients
ho have evidence of ischemia on DCMR. In
uture studies, including a larger patient cohort and
ardiac event rate, a significant difference between
hese patient groups can be expected. Furthermore,
n patients with DCMR without inducible WMA,
e found a similar cardiac event rate in those with
edical therapy only or early revascularization
3.1% vs. 3.2%; p  0.964), demonstrating that
here does not seem to be a benefit of early
evascularization in patients with DCMR without
nducible WMA (Fig. 3).
Hundley et al. (4) studied the outcome of 279
atients over a mean follow-up of 20 months. They
emonstrated that inducible WMA at DCMR
ere associated with future cardiac events in pa-
ients with normal and depressed LVEF (HR: 3.3;
I: 1.1 to 9.7; HR: 4.2; CI: 1.3 to 13.9), an effectndependent of the presence of risk factors for hAD. In a previous study in 461 patients, followed
or a median of 2.3 years by our working group, a
CMR without inducible WMA result was asso-
iated with a low cumulative event rate of 3.3% over
years (5). Inducible WMA detected by DCMR
redicted subsequent cardiac death or nonfatal MI
n univariate analysis (HR: 5.42; CI: 2.2 to 13.50;
 0.001, respectively). Our results, observed in a
arge patient cohort, are in congruence with these
revious reports, demonstrating the association of a
ositive DCMR with future cardiac events (HR:
.3; CI: 1.8 to 5.9; p 0.001). Dall’Armellina et al.
6) demonstrated, in 200 patients followed-up for a
edian of 60 months that inducible WMA were
ssociated with a greater risk of future events
eyond that associated with the resting EF and/or
ardiac risk factors (p  0.001). In addition, they
ere the only independent predictor in multivariate
nalysis (HR: 1.7; p 0.008). However, in this study,
n severe LV impairment (LVEF 40%), inducible
MA were not additionally predictive of outcome
ver LVEF at rest (6,19).
In previous studies of cardiac prognosis after
CMR a trend toward an association between the
umber of LV myocardial segments with inducible
MA and more frequent adverse events (4,20,21)
Figure 3. Kaplan-Meier Curves According to DCMR Result and
After Therapy
Kaplan-Meier curve analysis showing the difference in cumulative c
event rate when patients are stratiﬁed according to the occurrence
diac events by dobutamine cardiac magnetic resonance (DCMR) res
after therapy. Cardiac events were deﬁned as cardiac death (caused
stage heart failure, acute myocardial infarction [MI], or sudden card
death) and nonfatal MI.ardiac
of car-
ult and
by end-
iacas been demonstrated (7). In our large study
t
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170population in univariate analysis, there was no rela-
ionship between the number of LV myocardial seg-
ents with inducible WMA and incremental cardiac
vents. This is in congruence with DSE, in which HR
or prediction of cardiac events increased if 2 segments
emonstrated ischemia compared with the situation in
atients with “limited” ischemia (1 segment). How-
ver, there was no further increase in HR if  2
segments showed ischemia (14).
Most of our patients had an intermediate to high
pretest probability of CAD; therefore, these results
can be applicable to a wide spectrum of patients in
whom stress testing is clinically indicated. Identifi-
cation of patients at low risk of cardiac events
(negative DCMR) has an important impact on
management of patients with suspected CAD, by
avoiding the risk and the cost related to further
diagnostic and therapeutic approaches that are un-
likely to improve outcome in low-risk patients (22).
In addition, our results—obtained in a single
center with a high volume of DCMR—might be
applied to other centers, due to a known high
inter-institutional observer agreement in the inter-
pretation of DCMR (23), which is a clear advan-
tage of DSE (24). In addition, no ionizing radiation
needs to be applied during cardiac magnetic reso-
nance; therefore it can be repeated as necessary for
Figure 4. Kaplan-Meier Curves According to Cardiac Events or a
Kaplan-Meier curve analysis showing the difference in cumulative c
rence of cardiac events (A) or of any cardiac events (B) by DCMR. C
heart failure, acute MI, or sudden cardiac death) and nonfatal MI. A
larization by percutaneous coronary intervention; coronary artery b
heart failure warranting hospital admission. Abbreviations as in Figufollow-up purposes (25).Study limitations. The data presented were observed
only at a single center. Multicenter trials are needed
to confirm our results.
Due to the retrospective, observational approach,
follow-up could not be assessed in 100% of our
patients. Ninety-four patients (6%) were lost to
follow-up, due to incomplete patient datasets. We
cannot rule out that cardiac events occurred in the
patients with missing follow-up; however, patients
without complete follow-up included a significantly
lower proportion of subjects with previous CAD
and lower rate of inducible WMA compared with
patients with complete follow-up. Therefore, we do
not consider that this would have changed the
results of our study significantly.
In addition, patients with DCMR without in-
ducible WMA and inducible WMA were not
matched for demographic factors (e.g., risk factors,
age or other demographic factors). For that reason,
participants demonstrating inducible WMA at
DCMR showed significantly more diabetes, hyper-
tension, hyperlipoproteinemia, previous CAD, pre-
vious revascularization, a higher number of cardio-
vascular risk factors, and RWMA.
The decision for revascularization or medical
treatment was mainly made by the referring physi-
cian. Not all of our patients with a positive DCMR
Cardiac Events by DCMR
ac event rate when patients are stratiﬁed according to the occur-
iac events were deﬁned as cardiac death (caused by end-stage
ardiac events included cardiac events; noncardiac death; revascu-
s graft; ventricular arrhythmia; unstable angina, or congestive
2 and 3.ny
ardi
ard
ny c
ypaswere referred for invasive cardiac procedures. At the
G
c
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171time of DCMR, only 1 study had been published
about the short-term prognostic value of DCMR
(4). In addition, only 2 studies about the diagnostic
accuracy had been published (1,2). Therefore,
DCMR results were not always used for decision-
making (e.g., in favor of catheterization by the
referring physician). In patients with DCMR with-
out inducible WMA, 11.7% underwent early revas-
cularization. In comparison with patients with
DCMR without inducible WMA and medical
therapy, those with DCMR without inducible
WMA and early revascularization demonstrated a
significant higher risk profile. This might have
influenced the decision for early revascularization
versus medical treatment. In addition, a few of the
patients might have also refused further revascular-
ization even if ischemia was proven by inducible
WMA on DCMR.
Furthermore, segmental wall motion was visually
analyzed. Newer imaging protocols that involve
simultaneous assessment of WMA, myocardial per-
fusion, and late-gadolinium enhancement (LGE)
yield improved results in certain patient populations
(26). In addition, studies evaluating myocardial
strain with quantitative assessment of wall motion
by MRI tagging combined with rapid post-
processing algorithms might overcome this limita-
tion (27,28). Moreover, myocardial strain might
have prognostic value, because strain assessment
enables evaluation of border zone function, which
has been related to inducibility of monomorphic
ventricular tachycardia (29).
Currently, most cardiac magnetic resonance pro-
cedures involve the use of contrast media (25). LGEmagnetic resonance imaging in the Coll Cardiol 2008;52Recently it has been described that the amount of
myocardial scarring detected by cardiac magnetic
resonance is related to the long-term clinical out-
come (9,10) and might thus be a much better
predictor of lethal events than individual clinical
markers (30), which are limited by low positive
predictive values (31). As demonstrated by Kwong
et al. (32), the presence of LGE in patients with
chest pain referred for dobutamine stress might
serve as a marker of adverse cardiac prognosis.
Further studies combining DCMR and LGE
might offer additional prognostic information in
subjects with suspected ischemia (33).
C O N C L U S I O N S
In a large cohort of patients, DCMR has an added
value for predicting cardiac events during long-term
follow-up, improving the differentiation between
high-risk and low-risk patients. Patients with in-
ducible WMA and after early revascularization
demonstrate lower cardiac event rates than patients
with medical therapy alone. Further multicenter
trials are needed to assess the prognostic value of
DCMR.
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